t e c h n i c a l r e p o r t s
The Cre-loxP recombination system is the most widely used technology for in vivo tracing of stem or progenitor cell lineages. The precision of this genetic system largely depends on the specificity of Cre recombinase expression in targeted stem or progenitor cells. However, Cre expression in nontargeted cell types can complicate the interpretation of lineage-tracing studies and has caused controversy in many previous studies. Here we describe a new genetic lineage tracing system that incorporates the Dre-rox recombination system to enhance the precision of conventional Cre-loxPmediated lineage tracing. The Dre-rox system permits rigorous control of Cre-loxP recombination in lineage tracing, effectively circumventing potential uncertainty of the celltype specificity of Cre expression. Using this new system we investigated two topics of recent debates-the contribution of c-Kit + cardiac stem cells to cardiomyocytes in the heart and the contribution of Sox9 + hepatic progenitor cells to hepatocytes in the liver. By overcoming the technical hurdle of nonspecific Cre-loxP-mediated recombination, this new technology provides more precise analysis of cell lineage and fate decisions and facilitates the in vivo study of stem and progenitor cell plasticity in disease and regeneration.
During the process of differentiation, stem and progenitor cells make lineage choices that progressively narrow the range of cell types that can be generated, until the ultimate, differentiated cell type is formed. A cell's lineage captures its developmental trajectory from its progenitors, and a cell's fate is the differentiated cell type(s) that it will form. Unraveling cell lineage and fate determination provides fundamental information about stem cell function during development, disease and regeneration. Genetic lineage tracing is a powerful means to interrogate stem cell lineage and cell fate determination [1] [2] [3] [4] [5] [6] . The most widely used technology for in vivo stem cell tracking uses the Cre-loxP recombination system 7 . In transgenic mice that express Cre within a defined population of stem cells, Cre-mediated recombination removes loxPflanked transcriptional stop DNA sequences and permits expression of a reporter gene in the Cre + cells 8 . Because this form of genetic labeling is irreversible and heritable, the progeny of the Cre-marked cells continue to express the reporter gene, whether or not they actively express Cre. If a Cre-marked cell differentiates into a different cell type, then its expression of the genetic lineage reporter provides evidence that it belongs to the Cre-expressing lineage (Fig. 1a , scenario 1, cell type B (cell B) is derived from cell type A (cell A)).
Although Cre-loxP-based lineage tracing has provided unprecedented insights into mammalian development and into disease states, this technology has a technical hurdle that may sometimes confound interpretation of the results. The linchpin for accurate interpretation of Cre-loxP-based fate-mapping data is precise delineation of the pattern of Cre expression 9, 10 , as Cre expression in nontargeted cells could lead to the tracing of unintended lineages and confound interpretation of the fate-mapping data. For example, expression of a gene in both cell A and cell B can and often does occur. Cre labeling of both cell A and cell B cannot be used to formally conclude that cell A differentiates into cell B. Rather, this type of double labeling simply makes the genetic lineage tracing experiment uninterpretable. To properly infer that cell B is derived from cell A, one must exclude Cre-loxP recombination in cell B itself (Fig. 1a, scenario  2 , in which the inference that cell B arises from cell A is confounded by Cre expression in cell B). Because Cre-loxP-mediated recombination is sensitive, it can be technically challenging to fully exclude low level or infrequent Cre expression in nontargeted cells, creating a major hurdle for rigorous interpretation of the results of Cre-loxP-mediated genetic lineage tracing 10 . Here we present a new system that uses dual recombinases (Cre and Dre) and new reporter lines to resolve the unintentional lineage tracing issue and achieve more selective genetic tracing.
RESULTS

Generation of an interleaved dual reporter for exclusive recombination
To exclude genetic recombination in nontargeted cells, we generated a new genetic lineage tracing system that uses both the Cre-loxP and Dre-rox recombination systems. Similar to the Cre-loxP system, the Dre recombinase excises DNA regions flanked by rox recombination sites 11 . We first used mice that expressed these recombinases from the promoter of the widely expressed β-actin-expressing gene ACTB or from the synthetic promoter CAG (ACTB-Cre and CAG-Dre). We tested the activity and specificity of these transgenic mice using the recombinase-activated reporters R26-loxP-tdTomato (R26-loxP-stop-loxP-tdTomato) and R26-rox-tdTomato (R26-roxstop-rox-tdTomato). We found that the Cre and Dre recombinases specifically recognized the loxP and rox sites, respectively (Fig. 1b) , consistent with a previous report 12 . We took advantage of these orthogonal recombination systems and generated a reporter allele in the Rosa26 locus in which two pairs of recombination recognition sites were interleaved, such that successful Cre-loxP recombination would activate expression of the ZsGreen reporter, whereas successful Dre-rox recombination would activate expression of the tdTomato reporter (Fig. 1c) . We named this interleaved reporter (IR)-expressing mouse line IR1. Because the recombinase-recognition sites are interleaved (loxP-rox-loxP-rox), recombination by one system should inherently remove one recombinase-recognition site of the other system to render its reporter inert to subsequent recombination (for example, recombination using Dre-rox should remove one loxP site and prevent subsequent Cre-loxP-mediated recombination). Thus, in Figure 1a , scenario 2, programing cell B to express Dre first would preclude subsequent Cre-loxP-mediated recombination within this cell type.
To test this dual recombination system, we crossed the IR1 mouse line with lines that constitutively expressed Dre (CAG-Dre) or Cre (ACTB-Cre) (Fig. 1d) . As expected by IR1's design, whole-mount fluorescence and immunostaining of sections showed that expression of tdTomato but not of ZsGreen was activated in the CAG-Dre × IR1 mice, whereas expression of ZsGreen but not of tdTomato was activated in the ACTB-Cre × IR1 mice (Fig. 1e,f) . Similar results were obtained when the IR1 line was recombined with mouse lines that expressed recombinases that were inducible after treatment with tamoxifen 13 , because of the fusion of the recombinase with an engineered domain of the estrogen hormone receptor (ER) (Supplementary Fig. 1 ). We generated mice with an inducible CAG-Dre ER allele ( Supplementary Fig. 1a,b) , crossed them with the IR1 mice and evaluated expression of the reporter (Supplementary Fig. 1c ). Tamoxifen treatment resulted in the appearance of ZsGreen − tdTomato + cells in tissues of CAG-Dre ER × IR1 mice, whereas no recombination was detected in mice that had not been treated with tamoxifen (Supplementary Fig. 1d) . Similarly, ZsGreen + tdTomato − cells were observed in tissues of UBC-Cre ER × IR1 mice (UBC is broadly expressed in embryos following tamoxifen treatment) ( Supplementary  Fig. 1e,f ). These data demonstrate that the IR1 line is responsive to both constitutive and inducible Cre and Dre recombinases.
Constitutive Dre-rox recombination prevents inducible Cre-loxP recombination To test whether using recombination by one recombinase made the substrate unresponsive to the second recombinase, we exposed IR1 mice to constitutive Dre expression and inducible Cre ER expression. We reasoned that after constitutive Dre-rox recombination, a cell containing the interleaved reporter sequence would no longer undergo Cre-loxP recombination after treatment with tamoxifen. We elected to perform these proof-of-concept experiments in cardiomyocytes. We first generated a Tnni3-Dre allele, in which Dre expression is driven by regulatory elements of the cardiomyocyte-specific gene troponin I3 (Tnni3) (Supplementary Fig. 2a) . Tnni3-Dre expression specifically and efficiently labeled cardiomyocytes containing the R26-rox-tdTomato reporter or the interleaved reporter sequence, but not cardiomyocytes harboring the R26-loxP-tdTomato reporter ( Supplementary Fig. 2b-e) . We did not detect any Tnni3-Dre labeling of non-cardiomyocytes, such as endothelial cells, smooth muscle cells or fibroblasts (Supplementary Fig. 2f ), demonstrating that Tnni3-Dre strictly targeted cardiomyocytes. To test whether Dre-rox recombination precluded further Cre-mediated recombination, we generated Tnni3-Dre × αMHC-MerCreMer × IR1 mice-which contain Tnni3-Dre, the interleaved reporter sequence and a transgene expressing a tamoxifen-inducible Cre under the control of the cardiac-specific Myh6 gene promoter (A1cf Tg(Myh6-cre/Esr1*)1Jmk ; hereafter referred to as αMHC-MerCreMer)-and littermate control αMHC-MerCreMer × IR1 mice (Supplementary Fig. 3a) . In the hearts of adult αMHC-MerCreMer × IR1 mice, tamoxifen induction of Cre-mediated recombination labeled 98.21 ± 0.45% of cardiomyocytes with ZsGreen ( Supplementary Fig. 3b,c) . However, by using the same tamoxifen induction strategy, we did not detect any ZsGreen + cardiomyocytes in the hearts of Tnni3-Dre × αMHC-MerCreMer × IR1 mice, and all of the TNNI3 + cardiomyocytes were tdTomato + ( Supplementary Fig. 3b,c) . These data demonstrated that constitutive Dre recombination of the interleaved reporter sequence blocked further inducible Cre-loxP-mediated recombination in cardiomyocytes (Supplementary Fig. 3d ). Thus, Dre-rox-mediated recombination in this newly developed system could be used to preclude potential Cre-loxP-mediated recombination in Dre-expressing cells (for example, Fig. 1a , scenario 2, cell B).
Because this system relies on the dual recombinases acting on an interleaved reporter, we named it 'dual-recombinase-activated lineage tracing with interleaved reporter' (DeaLT-IR). After this experimental validation of the DeaLT-IR system for cell labeling, we next used it to address some uncertainties that have arisen from the possibility of unintentional lineage tracing in studies of putative resident stem cells in the heart and liver.
Unintentional cardiomyocyte tracing by Kit-Cre ER A noteworthy topic in the cardiovascular field is the myogenic fate of c-Kit + cardiac stem cells (CSCs) [14] [15] [16] [17] . In large part, this debate regarding the myogenic potential of CSCs originates from the uncertain specificity of Cre expression that is driven by regulatory elements of the Kit oncogene 18, 19 × IR1 mice, Dre first removes one loxP site and ZsGreen from the interleaved reporter allele in cardiomyocytes, precluding potential Cre-loxP-mediated labeling within cardiomyocytes. As a result, if tamoxifen activation of Kit-Cre ER in c-Kit + non-cardiomyocytes yielded ZsGreen + cardiomyocytes after cardiac injury, then one would conclude that this was due to cardiomyocyte differentiation from c-Kit + non-cardiomyocytes rather than from the labeling of cardiomyocytes themselves (Fig. 2a) . To achieve high labeling efficiency, we treated mice with tamoxifen 6-8 times between the neonatal and adult stages (Fig. 2b) . In hearts from adult Kit-Cre ER × IR1 mice, occasional ZsGreen + cardiomyocytes that were labeled by Kit-Cre ER expression were readily observed in addition to large numbers of ZsGreen + endothelial cells (Fig. 2c,d ). In contrast, we did not detect ZsGreen + cardiomyocytes in the hearts of Tnni3-Dre × Kit-Cre ER × IR1 mice, whereas we observed large numbers of ZsGreen + non-myocyte cells (Fig. 2c,d and Supplementary  Fig. 4a ). Similarly, no ZsGreen + tdTomato − cardiomyocytes were found after dissociating hearts from Tnni3-Dre × Kit-Cre ER × IR1 mice ( Supplementary Fig. 4b ). Quantitatively, 0.74 ± 0.11% cardiomyocytes were ZsGreen + tdTomato − in the hearts from Kit-Cre ER × IR1 mice after tamoxifen treatment from the neonatal to the adult stage ( Fig. 2e) . However, not a single ZsGreen + tdTomato − cardiomyocyte was detected after examination of over 500 sections from the hearts of four Tnni3-Dre × Kit-Cre ER × IR1 mice, using the same tamoxifen induction strategy (Fig. 2d,e) . Taken together, these results demonstrate that, in uninjured hearts, c-Kit + non-cardiomyocytes do not generate new cardiomyocytes; rather, cardiomyocytes labeled by Kit-Cre ER expression result from Cre activity in cardiomyocytes, in which the substrate is effectively removed by the new strategy.
Although not manifest in uninjured hearts, a latent myogenic potential of c-Kit + non-cardiomyocytes might be activated by myocardial injury. To test this hypothesis, we induced myocardial infarction (MI) in Kit-Cre ER × IR1 and Tnni3-Dre × Kit-Cre ER × IR1 mice (Fig. 2b) . The control condition was no operation (Fig. 2c-e and Supplementary Fig. 4 ). Four weeks after coronary artery ligation, we analyzed hearts for expression of the Cre genetic lineage tracer. We observed ZsGreen + tdTomato − cardiomyocytes in the hearts of KitCre ER × IR1 mice but not in the hearts of Tnni3-Dre × Kit-Cre ER × IR1 mice (Fig. 2f) . Similarly, no ZsGreen + tdTomato − cardiomyocytes were found after dissociating hearts from Tnni3-Dre × Kit-Cre ER × IR1 mice (Fig. 2g) . Whereas 0.78 ± 0.10% of cardiomyocytes were Crelabeled (ZsGreen + tdTomato − ) in infarcted hearts from Kit-Cre ER × IR1 mice, no Cre-labeled cardiomyocytes (ZsGreen + tdTomato − ) were observed in more than 500 heart sections that we examined from infarcted hearts from four Tnni3-Dre × Kit-Cre ER × IR1 mice (Fig. 2h,i) . We observed very few ZsGreen + tdTomato + cardiomyocytes (Fig. 2j) , consistent with fusion of c-Kit + cells with cardiomyocytes 16 . These data demonstrated that c-Kit + non-cardiomyocytes did not form de novo cardiomyocytes after injury (Fig. 2k) . Unlike cardiomyocytes, endothelial cells were comparably labeled by the conventional and new strategies (Fig. 2l,m) .
To independently address the myogenic potential of c-Kit + non-cardiomyocytes after cardiac injury, we generated a new Dre driver using another cardiomyocyte-specific marker, cardiac troponin T2 (Tnnt2-Dre) (Supplementary Fig. 5a ). Similarly to Tnni3-Dre, Tnnt2-Dre targeted cardiomyocytes specifically and efficiently ( Supplementary  Fig. 5b,c) . Next we generated a Tnnt2-Dre × Kit-Cre ER × IR1 mouse line that permits removal of a loxP site in Tnnt2-Dre-targeted cardiomyocytes (Supplementary Fig. 5d ). In the heart tissues from both mice that had been subjected to MI and those that had a sham surgery, we did not detect any ZsGreen + tdTomato − cardiomyocytes ( Supplementary Fig. 5e-g ), whereas endothelial cells were efficiently labeled ( Supplementary Fig. 5h,i) . Taken together, these results indicate that c-Kit + non-cardiomyocytes do not generate new cardiomyocytes after injury.
Genetic lineage switch uncovered by new strategy
We next asked whether the DeaLT-IR strategy was sensitive enough to uncover cell lineage conversion events, by studying the known conversion of hepatocytes into new biliary epithelial cells (BECs) after liver injury 21 as a proof of concept. We first generated a mouse line bearing an inducible, hepatocyte-specific Cre using regulatory elements from the albumin gene (Alb-Cre ER ) (Supplementary Fig. 6a ). After treatment of adult Alb-Cre ER × IR1 mice with tamoxifen, we detected the Cre-activated reporter ZsGreen in HNF4a + hepatocytes but not in KRT19 + (also known as CK19 + ) BECs (Supplementary Fig. 6b-d) .
We next generated a Krt19-Dre line, which constitutively labeled BECs and also a subset of hepatocytes ( Supplementary Fig. 6e-h ). We crossed both sets of mice to produce Krt19-Dre × Alb-Cre ER × IR1 mice (DeaLT-IR strategy), in which CK19 + BECs expressed tdTomato and in which most HNF4a + hepatocytes were marked by ZsGreen (Fig. 3a) . To test whether HNF4a + hepatocytes (ZsGreen + ) generated new CK19 + BECs after injury, we exposed Alb-Cre ER × IR1 and Krt19-Dre × Alb-Cre ER × IR1 mice to the liver toxin 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) or to bile duct ligation (BDL) surgery 22 , and we collected livers for analysis before and after injury ( Fig. 3b and Supplementary Fig. 7a ). After DDC-induced liver injury we found that there was substantial fibrotic tissue formation (Fig. 3c ) and ductal reaction (Fig. 3d) . Before DDC treatment, Alb-Cre ER expression labeled most of the hepatocytes and did not label BECs, as no ZsGreen + BECs were evident using either the conventional or new strategy (Fig. 3e) . After DDC-induced injury, a subset of CK19 + BECs expressed ZsGreen using either strategies (Fig. 3f) . Quantification of the percentage of ZsGreen + BECs showed that there was no difference in efficiency of hepatocyte-to-BEC conversion between the conventional and DeaLT-IR strategies (Fig. 3g) . Similarly, we found ZsGreen + BECs in livers from mice that had been subjected to BDL surgery ( Supplementary Fig. 7b-d) , consistent with a previous study 21 . Thus, even with rigorous exclusion of the possibility of unintentional Cre labeling using the new strategy, we detected the Cre hepatic lineage tracer in BECs, which was indicative of lineage conversion of hepatocytes to BECs (Fig. 3h) .
Generation of a nested reporter for two inducible recombinases
The DeaLT-IR strategy using the IR sequence reported above requires sequential recombination by Dre-rox first and then by Cre-loxP. However, at times it would be desirable for both Dre and Cre to be under tamoxifen control, for example, during embryonic development, albumin is expressed in hepatoblasts, which give rise to both hepatocytes and BECs 23 . Thus, the constitutive Alb-Dre line may target BECs in addition to hepatocytes, reducing its usefulness in distinguishing between the hepatocyte and BEC lineages. To accommodate temporally controlled Dre-rox recombination, we developed a second strategy in which inducible Dre-rox recombination controls Cre-mediated lineage tracing. This strategy uses dual recombinases with nested recombinase target sites, so that Dre-rox recombination removes loxP sites and the Cre-loxP readout, preventing CreloxP-mediated lineage tracing but not the reverse (Fig. 4a,b) . Toimplement this new strategy, we generated a mouse line expressing a new reporter allele, nested reporter 1 (NR1). Unlike the IR reporter, which requires sequential recombination, the NR1 sequence permits simultaneous expression of inducible Cre ER and Dre ER recombinases; however, similarly to the IR reporter, Dre-rox recombination controls Cre-mediated lineage tracing (Fig. 4a,b) 
Kit-Cre ER × IR1 bearing the NR1 reporter did not express fluorescent protein in the absence of Cre or Dre; they expressed tdTomato but not ZsGreen in the presence of CAG-Dre and expressed ZsGreen but not tdTomato in the presence of ACTB-Cre (Fig. 4c-e) . Having established the NR1 mouse line, we next used it to address a long-standing debate in liver regeneration. t e c h n i c a l r e p o r t s or substantially after injury 24, 25 . Whereas SOX9 is highly enriched in BECs, it is also weakly expressed in those hepatocytes that reside close to BECs, referred to as SOX9 + periportal hepatocytes 26 . Because expression of Sox9-Cre ER labels both BECs and a subset of periportal hepatocytes, it has been difficult to resolve whether SOX9 + BECs or SOX9 + hepatocytes give rise to new hepatocytes after injury. To address this question, we generated two inducible recombinase lines, Alb-Dre ER mice and Sox9-Cre ER mice ( Supplementary Fig. 8a,d) .
We verified the recombination pattern in Alb-Dre ER mice and in Sox9-Cre ER mice using the NR1 reporter. After tamoxifen treatment, the NR1 reporter sequence was selectively recombined in the hepatocytes that expressed Alb-Dre ER : ~99.9% HNF4a + hepatocytes and 0% CK19 + BECs were tdTomato + ZsGreen − in the liver of Alb-Dre ER × NR1 mice (Supplementary Fig. 8b,c) . This recombination pattern paralleled the Alb-Cre ER -mediated activation of a Cre-dependent reporter ( Supplementary Fig. 6a-d) . Consistent with a previous report 26 , Sox9-Cre ER expression activated the NR1 reporter in the majority of CK19 + BECs but also in a subset of HNF4a + hepatocytes ( Supplementary Fig. 8e,f) . Additionally, we generated a Alb-Dre ER × R26-rox-tdTomato × Sox9-Cre ER × R26-loxP-GFP mouse line and detected SOX9 + ALB + hepatocytes and SOX9 + ALB − BECs, along with SOX9 − ALB + hepatocytes, in the liver of these mice ( Supplementary  Fig. 9 ). Taken together, these data demonstrate that Sox9-Cre ER expression labels both BECs and a subset of hepatocytes. To test whether SOX9 + BECs gave rise to new hepatocytes after injury, we generated Alb-Dre ER × Sox9-Cre ER × NR1 mice (DeaLT with nested reporter (DeaLT-NR) strategy), as well as Sox9-Cre ER × NR1 littermate controls (conventional strategy) for side-by-side comparison. We performed tamoxifen treatment multiple times before liver injury and collected samples before and after the injury (Fig. 5a) . The DeaLT-NR strategy labeled SOX9 + BECs with ZsGreen, whereas SOX9 + periportal hepatocytes were labeled by tdTomato owing to excision of the Cre-activated reporter ZsGreen by Dre-rox recombination (Fig. 5b,c) . During the chase period, if chronic liver injury by treatment of the mice with carbon tetrachloride (CCl 4 ) induced BECs to differentiate into hepatocytes, then we would expect to observe the ZsGreen + tdTomato − lineage mark in a subset of hepatocytes following injury but not before it. Consistent with published results 26 , in pre-injury samples the conventional strategy using Sox9-Cre ER × NR1 mice labeled both BECs and periportal hepatocytes with ZsGreen (Fig. 5d,e and Supplementary Fig. 8f) . Quantitatively, 98.21 ± 0.85% CK19 + BECs and 7.89 ± 1.31% HNF4a + periportal hepatocytes expressed ZsGreen. With the DeaLT-NR strategy, in preinjury samples from the Alb-Dre ER × Sox9-Cre ER × NR1 mice, 98.82 ± 0.54% CK19 + BECs were labeled by ZsGreen (Fig. 5e) . However, no ZsGreen + tdTomato − HNF4a + hepatocytes were observed out of >400 liver sections from four mice, and >99.9% of the HNF4a + hepatocytes were tdTomato + (Fig. 5e) . These results indicated that Dre-rox recombination occurred efficiently in hepatocytes, where it abolished unwanted Cre-loxP recombination (Fig. 5b-e) . Thus, the DeaLT-NR strategy permits specific and efficient genetic labeling of SOX9 + BECs with ZsGreen and HNF4a + hepatocytes with tdTomato (Fig. 5e) . After injury, whole-mount fluorescence imaging showed that the percentage of ZsGreen + cells labeled by the conventional strategy increased substantially; however, this increase was not evident using the DeaLT-NR strategy (Fig. 5d) . Immunostaining of sections from injured livers that were labeled by the conventional strategy showed that 99.10 ± 0.53% CK19 + BECs and 15.71 ± 1.62% HNF4a + hepatocytes expressed ZsGreen. In contrast, using the DeaLT-NR strategy, 99.31 ± 0.34% CK19 + BECs expressed ZsGreen, and no ZsGreen + tdTomato − HNF4a + hepatocytes were observed (Fig. 5f ). These data indicated that after liver injury, SOX9 + BECs remained BECs and did not undergo lineage conversion into hepatocytes (Fig. 5g,h ). t e c h n i c a l r e p o r t s relative position of the recombinase sites and the fluorescent protein readouts. For the IR strategy, in addition to the IR1 mouse line, we established the IR2, IR3 and IR4 mouse lines (Fig. 6a) . We validated these reporters by activating them with CAG-Dre or ACTB-Cre (Fig. 6b-g ). These mouse reporter lines provide options to best fit the experimental system being studied. For example, some Cre or Cre ER lines co-express GFP or tdTomato, limiting the choice of the specific lineage-tracing readout. For the NR strategy, we generated another reporter allele (NR2) that permits Cre control of Dre recombinase (Supplementary Fig. 10a) . CAG-Dre or ACTB-Cre mice verified that this reporter yields the expected results (Supplementary Fig. 10b-e) . These mouse lines provide multiple options for lineage tracing, facilitating the application of the IR and NR strategies to diverse experimental settings.
Resources that expand the use of the IR and NR strategies
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DISCUSSION
Here we developed a new tracing strategy that uses dual recombinases to resolve the uncertainty that is potentially created by recombinase expression in nontargeted cells. Using interleaved or nested reporter designs, we showed that Dre-mediated recombination effectively blocked unwanted Cre activity and Cre reporter readout, thereby clarifying the interpretation of lineage tracing data. We then applied the DeaLT-IR or DeaLT-NR strategies in proof-of-concept studies to address two debates over the plasticity of stem cells in regenerative biology. First, we addressed the debate concerning the contribution of c-Kit + CSCs to the cardiomyocyte lineage [15] [16] [17] 20 . The observations that c-Kit + cells in the heart consist of both c-Kit + cardiomyocytes and c-Kit + non-cardiomyocytes and that Kit-Cre ER is expressed in cardiomyocytes during lineage tracing 20 has complicated the interpretation of lineage tracing studies. By taking into consideration, and controlling for, Kit-Cre ER activity in cardiomyocytes, we show that c-Kit + non-cardiomyocytes do not generate new cardiomyocytes in the postnatal heart during homeostasis and after injury. Our lineage tracing study does not directly address the question of whether cKit + cardiomyocytes can contribute to the formation of new cardiomyocytes after cardiac injury, but previous studies have reported that c-Kit + cells minimally contribute to cardiomyocytes after injury 16, 20, 27 . Our study focused on adult hearts and does not rule out the cardiomyogenic potential of c-Kit + CSCs in fetal hearts, as suggested by a recent study reporting that c-Kit + CSCs originating from neural crest possess full cardiomyogenic capacity at embryonic stages 28 . Second, we resolved the long-standing question on whether SOX9 + hepatic progenitors differentiate into new hepatocytes during liver regeneration. Using conventional Cre-loxP-mediated lineage tracing, previous studies were unable to determine the extent to which SOX9 + BEC-to-hepatocyte conversion occurs, because Sox9-Cre ER labels both SOX9 + BECs and a subset of periportal hepatocytes. By using our new strategy, we were able to label and trace SOX9 + BECs distinctly and avoid tracing of pre-existing SOX9 + hepatocytes. Our data support the conclusion that SOX9 + BECs adopt a ductal cell but not hepatocyte fate after injury, whereas SOX9 + hepatocytes expand to generate new hepatocytes, consistent with previous studies 24, 29, 30 .
To achieve selective lineage tracing, previous studies have used an intersectional recombinase strategy. Several alleles designed for an intersectional approach have been reported, including R26::FLAP 31 34, 35 . For these reporters, recombination by two different recombinases labels cells in which both recombinases are active with a distinct reporter, distinguishing them from cells labeled by only one of the recombinases. Similarly, we found that Cre and Dre drivers and their corresponding reporter alleles, when combined together in a single mouse, can distinguish single-from double-positive recombinase cells ( Supplementary  Fig. 9 ). Here we added a new set of reporters that enrich this rapidly evolving field for more precise lineage tracing (Supplementary Table 1) . Among these reporters, the interleaved set is unique because it reports on the temporal sequence of recombination, unlike the intersectional and nested strategies. In comparing the intersectional and nested strategies, the intersectional strategy is optimal for identifying cells in which both recombinases are active, whereas the nested strategy is designed to identify cells in which one recombinase and not the other is active (for NR1, Cre but not Dre is active; for NR2, Dre but not Cre is active). As compared with single-recombinasemediated tracing, the use of dual recombinases and their corresponding reporters enabled more stringent, accurate and sophisticated fate-mapping studies.
The IR or NR strategy not only provides more precise control of Cre recombinase and sets a higher technical standard for lineage tracing of Cre-expressing cells, but it also is sensitive enough to detect positive lineage-conversion events in vivo. By using hepatocyte-to-BEC conversion in liver injury as an example, our IR strategy was able to clearly demonstrate in vivo conversion of hepatocytes to BECs. Thus, this new strategy can be used to uncover cell fate switches while also rigorously controlling for potential nontargeted Cre-mediated lineage tracing.
As with any recombinase system, there are caveats to the use of these new lineage tracing strategies. Here we refer to a cell lineage as a population of cells that is labeled by a recombinase system. These population-level studies do not address the question of the types of cells that arise from individual precursor cells, which would require study of the clonal derivatives of individual precursors. However, we note that the recombinase systems described in this study could be used for clonal analyses.
The DeaLT-IR and DeaLT-NR systems require a Cre-expressing mouse line, a Dre-expressing mouse line, and the appropriate reporter line. Because we have already generated and validated several reporters, and Cre lines are often widely available, application of these new strategies will typically require generation of a Dre mouse line (Supplementary Fig. 11a) . We propose that when a positive lineage result is detected by single-recombinase-mediated tracing, but there is uncertainty regarding the expression of Cre or the gene that drives Cre, our systems could be used for further fate mapping. A robust promoter should be selected to drive expression of Dre or Dre ER , because incomplete or inefficient recombination by Dre or Dre ER would not fully preclude unintentional Cre-loxP-mediated recombination in Dreexpressing cells. Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) after the Dre cDNA sequence could be considered for the purpose of stabilizing the Dre-encoding mRNA and increasing Dre protein levels, which might result in greater recombination efficiency. Furthermore, the specificity of the genetic elements available to express Dre in cell B is critical to the overall experimental design and to the choice of Dre or Dre ER : if promoter B is specific to cell B throughout all stages of development, then the use of Dre and an interleaved reporter would be most effective, but if promoter B is specific only within a given time window, then use of Dre ER and a nested reporter are recommended (Supplementary Fig. 11a ).
In summary, by taking advantage of established and widely used Cre-loxP-based genetic tools, we have developed the DeaLT-IR and DeaLT-NR strategies to permit unambiguous determination of the contribution of one genetic lineage to another. These strategies are intended to reduce ambiguity in lineage tracing studies caused by uncertainty as to whether Cre is expressed in pre-existing, nontargeted cells (Supplementary Fig. 11b ). These new strategies and reagents provide the means to more precisely dissect cell origin and fate, without invasive manipulation or cell transplantation [36] [37] [38] , in multiple fields of research.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Quantification of labeled cardiomyocytes and endothelial cells. Mouse hearts were collected and embedded for serial coronal sectioning. For each adult heart, all of the collected sections were put on 52 to 65 positively charged slides, with six slides to a set, and each slide contained 8-10 heart sections. Slides were stained for TNNI3 and ZsGreen. Myocardial infarction in adult mice. Adult mice (9-12 weeks of age) were subjected to surgical manipulation as described previously 49 . Briefly, mice on a heated pad were anesthetized with 2% isoflurane gas through tracheal intubation. When the mouse did not respond to a tail and toe pinch, its limbs were fixed on the pad, and its chest was disinfected with iodine. A vertical 1-cm incision was made at the chest skin, and a blunt dissection of the muscle and fascia was performed to avoid injuring the blood vessels. After making a 1-cm incision between the third and fourth intercostal ribs, the internal chest was exposed for subsequent operation. Then the left anterior descending (LAD) branch of the coronary artery was permanently ligated with a 0-8 suture. The ligation was judged to be successful when the heart showed signs of cyanosis. The incision was closed with a 6-0 suture, and air was discharged from the chest. The surgical incision was disinfected, and the mice were supplied with pure oxygen for 4-5 min until they resumed spontaneous breathing. Then the tracheal intubation tube was removed, and the mice were kept warm until recovery of normal behavior followed by treatment with analgesics. In the sham-operated control group, the same procedure was followed, except that the ligation of the LAD coronary artery was omitted. The person who performed the surgery was blinded to the allocation of the different experimental groups.
Cardiomyocyte isolation. Adult cardiomyocytes were isolated as described previously 20 . Briefly, adult mice were injected with 200 µl heparin (6.25 U/µl) intraperitoneally to prevent coagulation of blood in the coronary arteries. Twenty minutes later, the mice were anesthetized with sodium pentobarbital (80 mg per kg body weight) by intraperitoneal injection, followed by an interval of 5-10 min until the mice stopped responding to tail and toe pinches. Then the hearts were dissected and ligated to a perfusion-fluid-filled aortic cannula, and these were then perfused with perfusion buffer (137 mM NaCl, 4 mM KCl, 0.33 mM NaH 2 PO 4 , 1 mM MgCl 2 , 10 mM HEPES, 5 mM taurine, 10 mM 2,3-butanedione monoxime (BDM; B0753, Sigma)) and 10 mM glucose, pH 7.4) at a flow rate of 4 ml/min for ~5 min, until the effluent became clear. The perfusion liquid was switched to digestion buffer (perfusion buffer containing 0.1 mg/µl collagenase II and 0.08 mg/µl protease XIV) and perfused for 12-15 min at the same flow rate. The digested hearts were transferred to transfer buffer (perfusion buffer containing 0.5 mg/ml BSA), minced by forceps and filtered through a 100-µm strainer. The isolated cells were centrifuged for 3 min at 20g to pellet the cardiomyocytes, which were subsequently resuspended in transfer buffer for further analysis.
Models of liver injury.
Mice that were treated with 5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), carbon tetrachloride (CCl 4 ) or bile duct ligation (BDL) were used as models of liver injury. All of the treatments in to cause liver injury were performed at 2 weeks after tamoxifen treatment. For the DDC model of chronic liver injury, adult mice (11 weeks of age) were given 0.1% wt/wt DDC (Sigma-Aldrich) in PMI Mouse Diet (#5015, Harlan Teklad) for 8 weeks; control mice were fed with PMI Mouse diet. For the CCl 4 model of chronic liver injury, CCl 4 was dissolved in corn oil (1:3) first, and then the mice (11 weeks of age) were given CCl 4 (1 µl per g body weight) by intraperitoneal injection once every 3 d for a total of 15 injections. Control mice received the equivalent amount of corn oil. The BDL model of liver injury was performed according to established protocols 50 . Adult mice (11 weeks of age) were anesthetized with 2% isoflurane gas in a sealed chamber. The abdominal fur was then removed, and the skin was disinfected with iodine. The mice were transferred onto a 37 °C heating pad, and anesthesia was maintained by inhalation of isoflurane. A midline abdominal incision was made to expose the liver. The common bile duct was ligated twice with 4-0 silk sutures. After the ligation, the skin incisions were closed with a 6-0 suture, and the mice were supplied with pure oxygen for 4-5 min until they resumed normal breathing. Then the tracheal intubation tube was removed, and the mice were kept warm until recovery of normal behavior. In the shamoperated group, the same procedure was followed, except that the common bile duct was not ligated.
Statistical analysis. All data were determined from three or four independent experiments as indicated in each figure legend and are presented as mean values ± s.e.m. All mice were randomly assigned to different experimental groups. Statistical comparisons between data sets were made with analysis of normality and variance. A two-sided unpaired Student's t-test was used for comparing differences between two groups. The null hypothesis was rejected for P < 0.05.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Graph Pad Prism 5.0 was used for data analysis. Image J and Photoline was used for image analysis of immunofluorescence and histochemistry.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All unique materials are readily available from the authors or from standard commercial resources.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
We show the antibodies in Online Methods. We included the catalogue number for each commercial antibody used, so more detailed information could be obtained from the companies. In addition, we added the dilution for each antibody in our immunostaining so readers could follow the protocol for staining. The antibodies used were as follows: tdTomato (Rockland, 600-401-379; 1:1,000 dilution), TNNI3 (Abcam, ab56357; 1:100 dilution), CDH5 (R&D, AF1002; 1:100 dilution), PECAM (BD Pharmingen, 553370; 1:500 dilution), αSMA (Sigma, F3777; 1:500 dilution), PDGFRa (eBioscience, 14-1401-81; 1:500 dilution), CK19 (DSHB, TROMA-III; 1:500 dilution), HNF4a (Santa Cruz, sc-6556; 1:100 dilution), GFP (Abcam, ab6662; 1:100 dilution).
